vs
德康医疗（DXCM）与Sunrun Inc.（RUN）财务数据对比。点击上方公司名可切换其他公司
德康医疗的季度营收约是Sunrun Inc.的1.1倍（$1.3B vs $1.2B），德康医疗净利率更高（21.2% vs 8.9%，领先12.3%），Sunrun Inc.同比增速更快（123.5% vs 21.6%），过去两年Sunrun Inc.的营收复合增速更高（59.0% vs 12.0%）
德康医疗是美国跨国医疗保健企业，专注于研发、生产及销售糖尿病管理领域的连续血糖监测（CGM）系列系统。其全球总部及研发中心位于美国加利福尼亚州圣地亚哥，生产基地分布于美国亚利桑那州梅萨、马来西亚峇都交湾及爱尔兰戈尔韦郡阿斯里。
Sunrun Inc.是美国知名的光伏系统及电池储能产品供应商，业务以服务住宅客户为主，2007年成立，总部位于加利福尼亚州旧金山，致力于为家庭用户提供高效的清洁能源解决方案。
DXCM vs RUN — 直观对比
营收规模更大
DXCM
是对方的1.1倍
$1.2B
营收增速更快
RUN
高出101.9%
21.6%
净利率更高
DXCM
高出12.3%
8.9%
两年增速更快
RUN
近两年复合增速
12.0%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.3B | $1.2B |
| 净利润 | $267.3M | $103.6M |
| 毛利率 | 62.9% | — |
| 营业利润率 | 25.6% | 8.4% |
| 净利率 | 21.2% | 8.9% |
| 营收同比 | 21.6% | 123.5% |
| 净利润同比 | 153.6% | 103.7% |
| 每股收益（稀释后） | $0.67 | $0.38 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DXCMRUN
| Q1 26 | $1.3B | — | ||
| Q4 25 | $1.3B | $1.2B | ||
| Q3 25 | $1.2B | $724.6M | ||
| Q2 25 | $1.2B | $569.3M | ||
| Q1 25 | $1.0B | $504.3M | ||
| Q4 24 | $1.1B | $518.5M | ||
| Q3 24 | $994.2M | $537.2M | ||
| Q2 24 | $1.0B | $523.9M |
净利润DXCMRUN
| Q1 26 | $267.3M | — | ||
| Q4 25 | $267.3M | $103.6M | ||
| Q3 25 | $283.8M | $16.6M | ||
| Q2 25 | $179.8M | $279.8M | ||
| Q1 25 | $105.4M | $50.0M | ||
| Q4 24 | $151.7M | $-2.8B | ||
| Q3 24 | $134.6M | $-83.8M | ||
| Q2 24 | $143.5M | $139.1M |
毛利率DXCMRUN
| Q1 26 | 62.9% | — | ||
| Q4 25 | 62.9% | — | ||
| Q3 25 | 60.5% | — | ||
| Q2 25 | 59.5% | — | ||
| Q1 25 | 56.9% | — | ||
| Q4 24 | 58.9% | — | ||
| Q3 24 | 59.7% | — | ||
| Q2 24 | 62.4% | — |
营业利润率DXCMRUN
| Q1 26 | 25.6% | — | ||
| Q4 25 | 25.6% | 8.4% | ||
| Q3 25 | 20.1% | 0.5% | ||
| Q2 25 | 18.4% | -19.7% | ||
| Q1 25 | 12.9% | -22.8% | ||
| Q4 24 | 17.0% | -628.0% | ||
| Q3 24 | 15.3% | -23.8% | ||
| Q2 24 | 15.7% | -24.4% |
净利率DXCMRUN
| Q1 26 | 21.2% | — | ||
| Q4 25 | 21.2% | 8.9% | ||
| Q3 25 | 23.5% | 2.3% | ||
| Q2 25 | 15.5% | 49.1% | ||
| Q1 25 | 10.2% | 9.9% | ||
| Q4 24 | 13.6% | -542.7% | ||
| Q3 24 | 13.5% | -15.6% | ||
| Q2 24 | 14.3% | 26.5% |
每股收益（稀释后）DXCMRUN
| Q1 26 | $0.67 | — | ||
| Q4 25 | $0.67 | $0.38 | ||
| Q3 25 | $0.70 | $0.06 | ||
| Q2 25 | $0.45 | $1.07 | ||
| Q1 25 | $0.27 | $0.20 | ||
| Q4 24 | $0.37 | $-12.59 | ||
| Q3 24 | $0.34 | $-0.37 | ||
| Q2 24 | $0.35 | $0.55 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $917.7M | — |
| 总债务越低越好 | — | $14.7B |
| 股东权益账面价值 | $2.7B | $3.1B |
| 总资产 | $6.3B | $22.6B |
| 负债/权益比越低杠杆越低 | — | 4.69× |
8季度趋势，按日历期对齐
现金及短期投资DXCMRUN
| Q1 26 | $917.7M | — | ||
| Q4 25 | $917.7M | — | ||
| Q3 25 | $1.8B | — | ||
| Q2 25 | $1.2B | — | ||
| Q1 25 | $904.9M | — | ||
| Q4 24 | $606.1M | — | ||
| Q3 24 | $621.2M | — | ||
| Q2 24 | $939.2M | — |
总债务DXCMRUN
| Q1 26 | — | — | ||
| Q4 25 | — | $14.7B | ||
| Q3 25 | — | $14.6B | ||
| Q2 25 | — | $14.0B | ||
| Q1 25 | — | $13.6B | ||
| Q4 24 | — | $12.9B | ||
| Q3 24 | — | $12.5B | ||
| Q2 24 | — | $12.0B |
股东权益DXCMRUN
| Q1 26 | $2.7B | — | ||
| Q4 25 | $2.7B | $3.1B | ||
| Q3 25 | $2.7B | $3.0B | ||
| Q2 25 | $2.6B | $2.9B | ||
| Q1 25 | $2.3B | $2.6B | ||
| Q4 24 | $2.1B | $2.6B | ||
| Q3 24 | $2.0B | $5.3B | ||
| Q2 24 | $2.4B | $5.4B |
总资产DXCMRUN
| Q1 26 | $6.3B | — | ||
| Q4 25 | $6.3B | $22.6B | ||
| Q3 25 | $7.5B | $22.2B | ||
| Q2 25 | $7.3B | $21.2B | ||
| Q1 25 | $6.8B | $20.4B | ||
| Q4 24 | $6.5B | $19.9B | ||
| Q3 24 | $6.4B | $22.1B | ||
| Q2 24 | $6.8B | $21.4B |
负债/权益比DXCMRUN
| Q1 26 | — | — | ||
| Q4 25 | — | 4.69× | ||
| Q3 25 | — | 4.90× | ||
| Q2 25 | — | 4.80× | ||
| Q1 25 | — | 5.19× | ||
| Q4 24 | — | 5.05× | ||
| Q3 24 | — | 2.36× | ||
| Q2 24 | — | 2.23× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $96.9M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | — | 0.94× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流DXCMRUN
| Q1 26 | — | — | ||
| Q4 25 | $294.0M | $96.9M | ||
| Q3 25 | $659.9M | $-121.5M | ||
| Q2 25 | $303.0M | $-292.7M | ||
| Q1 25 | $183.8M | $-104.2M | ||
| Q4 24 | $301.4M | $-258.4M | ||
| Q3 24 | $199.5M | $-156.2M | ||
| Q2 24 | $279.4M | $-208.5M |
自由现金流DXCMRUN
| Q1 26 | — | — | ||
| Q4 25 | $192.1M | — | ||
| Q3 25 | $579.4M | — | ||
| Q2 25 | $208.9M | — | ||
| Q1 25 | $96.8M | — | ||
| Q4 24 | $176.8M | — | ||
| Q3 24 | $88.3M | $-156.4M | ||
| Q2 24 | $213.3M | — |
自由现金流率DXCMRUN
| Q1 26 | — | — | ||
| Q4 25 | 15.3% | — | ||
| Q3 25 | 47.9% | — | ||
| Q2 25 | 18.1% | — | ||
| Q1 25 | 9.3% | — | ||
| Q4 24 | 15.9% | — | ||
| Q3 24 | 8.9% | -29.1% | ||
| Q2 24 | 21.2% | — |
资本支出强度DXCMRUN
| Q1 26 | — | — | ||
| Q4 25 | 8.1% | — | ||
| Q3 25 | 6.7% | — | ||
| Q2 25 | 8.1% | — | ||
| Q1 25 | 8.4% | — | ||
| Q4 24 | 11.2% | — | ||
| Q3 24 | 11.2% | 0.0% | ||
| Q2 24 | 6.6% | — |
现金转化率DXCMRUN
| Q1 26 | — | — | ||
| Q4 25 | 1.10× | 0.94× | ||
| Q3 25 | 2.33× | -7.33× | ||
| Q2 25 | 1.69× | -1.05× | ||
| Q1 25 | 1.74× | -2.08× | ||
| Q4 24 | 1.99× | — | ||
| Q3 24 | 1.48× | — | ||
| Q2 24 | 1.95× | -1.50× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DXCM
暂无分部数据
RUN
| Products | $692.3M | 60% |
| Customer Agreements | $435.2M | 38% |
| Manufactured Product Other | $56.7M | 5% |
| Incentives | $31.3M | 3% |
